Why Is FIRST TRACKS BIOTHER (TRAX) Stock Up Today?
By the Top Tier Newswire AI Desk · reviewed against 11 wire stories
FIRST TRACKS BIOTHER (TRAX) is up +7.25% in the latest session. Our newswire has captured 11 stories on TRAX across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for TRAX publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
TRAX · today's session (5-min) · +7.25% vs prior close · updated 12:13 PM ETAI sentiment, last 36h · averaged over 11 stories · 65/100 bullish
The headlines behind the move
Story flow · 10 stories on the wire, last 36h · hover or tap a dot for the headline
1h agoMarketChameleonBULLISH 63Product/PR
TRAX jumps ahead of Oct. 12 webcast as First Tracks tees up Phase 1b ANB033 celiac data
First Tracks Biotherapeutics (TRAX) said it will release top-line data from Cohort 1 of its global Phase 1b trial of ANB033 in celiac disease on Oct. 12, 2026, followed by an 8:30 a.m. ET investor webcast. The company described Cohort 1 as a gluten-challenge study assessing prevention of mucosal damage, setting a clear near-term catalyst for investors watching the stock’s move during market hours.
2h agoInvestors.comBULLISH 74Product/PR
Why This IPO Stock, An AnaptysBio Spinoff, Just Skyrocketed More Than 25%
First Tracks Biotherapeutics posted "impressive" results for its celiac disease treatment Monday, and the IPO stock surged.
3h agoInvestorsHubBULLISH 74Product/PR
First Tracks Biotherapeutics Shares Jump 20% After Positive Phase 1b Celiac Disease Trial Results
First Tracks Biotherapeutics shares surge 20% after ANB033 delivers positive Phase 1b celiac disease results, with further trials planned for 2027.
4h agoThe FlyBULLISH 56Product/PR
First Tracks Biotherapeutics reports results from Cohort 1 of ANB033 trial
4h agoMarketChameleonBULLISH 67Product/PR
TRAX highlights ANB033’s Week 6 celiac data: intestinal protection with fewer symptom-mitigation meds
October 12, 2026
First Tracks Biotherapeutics (TRAX) reported positive top-line Phase 1b Cohort 1 results for ANB033 in a 14-day gluten-challenge study in celiac disease, with statistically significant separation from placebo on multiple histologic endpoints at Week 6. The company also highlighted symptom control during the challenge, including lower CDSD scores early in the challenge window and lower use of permitted GI symptom medications on ANB033 (6%) versus placebo (47%).
4h agoInvesting.com MarketsBULLISH 72General
Why is First Tracks Biotherapeutics stock surging today?
Why is First Tracks Biotherapeutics stock surging today?
5h agoInvesting.com MarketsBULLISH 74Product/PR
First Tracks Biotherapeutics stock surges 20% on celiac trial data
First Tracks Biotherapeutics stock surges 20% on celiac trial data
5h agoSeeking AlphaBULLISH 58General
At a glance: stocks gapping up premarket
Stock market premarket gap-ups Monday: see top movers like TRAX, CCC, XRPN & MIRM, plus what big bank earnings and inflation data mean—read now.
5h agoBusiness InsiderBULLISH 74Product/PR
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.
20h agoBusiness InsiderNEUTRAL 53Product/PR
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory...
Frequently asked questions
Why is TRAX stock up today?
FIRST TRACKS BIOTHER (TRAX) is up +7.25% in the latest session. Our newswire has captured 11 stories on TRAX across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 65/100). The most recent driver: "TRAX jumps ahead of Oct. 12 webcast as First Tracks tees up Phase 1b ANB033 celiac data" (MarketChameleon).
Is TRAX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of TRAX coverage reads 65/100 over 11 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →